• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症临床试验中生活质量数据缺失:严重问题与挑战

Missing quality of life data in cancer clinical trials: serious problems and challenges.

作者信息

Bernhard J, Cella D F, Coates A S, Fallowfield L, Ganz P A, Moinpour C M, Mosconi P, Osoba D, Simes J, Hürny C

机构信息

SIAK Coordinating Center, Bern, Switzerland.

出版信息

Stat Med. 1998;17(5-7):517-32. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<517::aid-sim799>3.0.co;2-s.

DOI:10.1002/(sici)1097-0258(19980315/15)17:5/7<517::aid-sim799>3.0.co;2-s
PMID:9549801
Abstract

Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other important sources are potentially avoidable and can broadly be divided into three categories: (i) methodological factors; (ii) logistic and administrative factors; (iii) patient-related factors. Logistic and administrative factors, for example, staff oversights, have proven to be most important. Since most QOL measurements require patient self-report, it is usually not possible to rectify the failure to collect baseline data or any follow-up assessments. There is strong evidence that such data are not 'missing at random', and cannot be ignored without introducing bias. Although several approaches to the analysis of partly missing data have been described, none is entirely satisfactory. Prevention of avoidable missing data is better than attempted cure. In July 1996, an international conference on missing QOL data in cancer clinical trials reported the experience of most major groups involved. This paper will serve as an introduction to the problem and provide an estimation of its magnitude, and approaches to its prevention and solution.

摘要

近年来,随着越来越多的研究团队认识到此类终点的重要性,癌症临床试验中生活质量(QOL)的测量有所增加。一个关键问题是数据缺失。一些生活质量数据可能不可避免地缺失,例如当患者病情太重而无法完成表格时。其他重要来源可能是可以避免的,大致可分为三类:(i)方法学因素;(ii)后勤和管理因素;(iii)患者相关因素。例如,后勤和管理因素,如工作人员疏忽,已被证明是最重要的。由于大多数生活质量测量需要患者自我报告,通常无法纠正未能收集基线数据或任何随访评估的情况。有强有力的证据表明,此类数据并非“随机缺失”,若不加以考虑则会引入偏差。尽管已经描述了几种分析部分缺失数据的方法,但没有一种是完全令人满意的。预防可避免的缺失数据比试图补救更好。1996年7月,一次关于癌症临床试验中生活质量数据缺失的国际会议报告了大多数主要研究团队的经验。本文将介绍该问题,估计其严重程度,并探讨预防和解决该问题的方法。

相似文献

1
Missing quality of life data in cancer clinical trials: serious problems and challenges.癌症临床试验中生活质量数据缺失:严重问题与挑战
Stat Med. 1998;17(5-7):517-32. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<517::aid-sim799>3.0.co;2-s.
2
Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research.瑞士临床癌症研究组织开展的多中心试验中生活质量评估的实际问题。
Stat Med. 1998;17(5-7):633-9. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<633::aid-sim810>3.0.co;2-u.
3
Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions.东部肿瘤协作组(ECOG)临床试验中生活质量研究的缺失数据:问题与解决方案
Stat Med. 1998;17(5-7):547-59. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<547::aid-sim802>3.0.co;2-f.
4
Why are missing quality of life data a problem in clinical trials of cancer therapy?为什么生活质量数据缺失在癌症治疗临床试验中是个问题?
Stat Med. 1998;17(5-7):667-77. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<667::aid-sim813>3.0.co;2-6.
5
Ensuring the quality of quality of life data: the Southwest Oncology Group experience.确保生活质量数据的质量:西南肿瘤协作组的经验
Stat Med. 1998;17(5-7):641-51. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<641::aid-sim811>3.0.co;2-w.
6
Identifying the types of missingness in quality of life data from clinical trials.识别来自临床试验的生活质量数据中的缺失类型。
Stat Med. 1998;17(5-7):739-56. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<739::aid-sim818>3.0.co;2-m.
7
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial.晚期结直肠癌临床试验中生活质量数据非随机缺失所带来的挑战。
Psychooncology. 2000 Jul-Aug;9(4):340-54. doi: 10.1002/1099-1611(200007/08)9:4<340::aid-pon466>3.0.co;2-f.
8
Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer.生活质量作为欧洲癌症研究与治疗组织(EORTC)临床试验的终点指标。欧洲癌症研究与治疗组织
Stat Med. 1998;17(5-7):561-9. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<561::aid-sim803>3.0.co;2-s.
9
Compliance with QOL assessment in multi-centre German breast cancer trials.德国多中心乳腺癌试验中生活质量评估的依从性。
Stat Med. 1998;17(5-7):571-5. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<571::aid-sim804>3.0.co;2-o.
10
Practical approaches to minimize problems with missing quality of life data.
Stat Med. 1998;17(5-7):725-37. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<725::aid-sim817>3.0.co;2-1.

引用本文的文献

1
Enhancing representativeness of patient-reported outcomes in routine radiation oncology care: a quality improvement protocol to address non-response.提高常规放射肿瘤学护理中患者报告结局的代表性:一项解决无应答问题的质量改进方案。
BMJ Open. 2024 Dec 12;14(12):e097127. doi: 10.1136/bmjopen-2024-097127.
2
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).迈向骨髓增生异常综合征/肿瘤(MDS)患者临床试验中更以患者为中心的药物研发过程:来自国际MDS联盟(icMDS)的实际考量
Hemasphere. 2024 May 21;8(5):e69. doi: 10.1002/hem3.69. eCollection 2024 May.
3
Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
系统治疗对转移性结直肠癌患者健康相关生活质量的影响:系统评价和网络荟萃分析。
BMC Cancer. 2024 Feb 9;24(1):188. doi: 10.1186/s12885-024-11937-z.
4
Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy.新辅助放化疗和食管切除术后食管癌患者短期和长期健康相关生活质量的预测特征。
Ann Surg Oncol. 2023 Dec;30(13):8192-8202. doi: 10.1245/s10434-023-14028-8. Epub 2023 Aug 16.
5
Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews.知识转化对 CONSORT-PRO 扩展报告指南的关注:综述的综述。
Qual Life Res. 2022 Oct;31(10):2939-2957. doi: 10.1007/s11136-022-03119-w. Epub 2022 Mar 26.
6
Patient-Reported Outcomes Assessing the Impact of Palliative Radiotherapy on Quality of Life and Symptom Burden in Head and Neck Cancer Patients: A Systematic Review.患者报告结局:评估姑息性放疗对头颈癌患者生活质量和症状负担的影响:一项系统综述
Front Oncol. 2021 Jun 4;11:683042. doi: 10.3389/fonc.2021.683042. eCollection 2021.
7
Electronic forms for patient reported outcome measures (PROMs) are an effective, time-efficient, and cost-minimizing alternative to paper forms.电子形式的患者报告结局测量(PROMs)是一种有效、省时且降低成本的纸质表单替代方式。
Pediatr Rheumatol Online J. 2021 May 3;19(1):67. doi: 10.1186/s12969-021-00551-z.
8
Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.根据CONSORT声明,胶质母细胞瘤患者随机对照试验中患者报告结局的报告质量。
Neurooncol Pract. 2020 Nov 11;8(2):148-159. doi: 10.1093/nop/npaa074. eCollection 2021 Apr.
9
Characteristics and patient-reported outcomes associated with dropout in severely affected oncological patients: an exploratory study.严重肿瘤患者脱落的特征和患者报告结局:一项探索性研究。
BMC Med Res Methodol. 2021 Apr 20;21(1):77. doi: 10.1186/s12874-021-01259-0.
10
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.来那度胺维持治疗对 R-CHOP 方案治疗后达缓解的弥漫性大 B 细胞淋巴瘤患者的疗效:来自随机对照 REMARC 研究的生存质量、剂量和安全性结果。
Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.